- Entry
- $0.53
- Now
- $0.5262 -0.7%
- Target
- $2.50
- Score
- —
I've been following this ticker for quite some time and I figured I'd make this post because I feel like the recent developments are quite interesting. After their phase 3 failed to meet the endpoint by, quote, "a handful" of patients but showed statistically significant benefits this was an interesting stock to follow. This week couple important things happened - Leerink presentation and a day later an SEC filing which would allow them to double the **authorized** shares from 170M …
— ORIGINAL POST ·
$ATYR - comeback story? Catalyst cluster: Recent Leerink presentation, SEC filings, re-iterated buy ratings, insider buying and macro FDA situation paint a new picture
· r/Shortsqueeze
· Mar 14, 2026